Frost & Sullivan Independent Equity Research
Entera Bio developed a delivery platform for replacing injections with pills; the Company has two drugs in clinical phases; market potential for their platform is significant; Entera Bio recently entered into a $270 million license agreement with Amgen; price target is set at $17.6
![enteralogo1 enteralogo1](https://www.frostequityresearch.com/wp-content/uploads/elementor/thumbs/enteralogo1-odb6s7n3xxosmgicz04bfxnvv6ad7s0tuegrc2rb1s.png)
Company: Entera Bio
Sector: Healthcare
Report type: Initiation Report
Published on: July 1, 2019